Previsión

El precio objetivo medio de los analistas es de 31,19 € (+56,34 %). La mediana es de 33,66 € (+68,72 %).

Comprar	14
Mantener	2
Vender	0

Noticias Ir al feed de noticias

Viridien reports strong order growth; stock jumps after Q2 data

Viridien’s stock rose about 14.7% after Q2 figures following a marked increase in the order backlog in geosciences to USD 306m (up 33% since March). Major project awards from IOCs and NOCs in the Gulf of Mexico, Africa and the Middle East drove the volume; analysts view this as an early sign of broader revenue recovery. The EDA segment reached an adjusted EBITDA margin of 60% and the company confirmed its full-year target of USD 100m net cash flow for 2026. Viridien also filed the interim report with the AMF, providing additional transparency and investor confidence. » Más en de.investing.com
Viridian Therapeutics' Lumvoa seen as differentiated treatment for thyroid eye disease, analysts raise targets

Goldman Sachs raised its target for Viridian Therapeutics to $39 and kept a Buy rating, citing Lumvoa's stronger proptosis improvement, promising safety profile and more convenient dosing versus Tepezza. Truist raised its target to $38, reiterated Buy and highlighted Lumvoa's focus on underserved markets, parity pricing and projected significant 2027 revenue with a franchise extension planned for Q1 2027. Viridian's broader pipeline includes Veligrotrug, Elegrobart, an anti‑TSHR program and FcRn inhibitors VRDN‑008 and VRDN‑006. » Más en finance.yahoo.com
Viridien expects markedly negative quarterly result and issues annual forecast

Viridien will release results for the quarter ended June 30, 2026 on July 30, 2026; one analyst estimates EPS for the most recent quarter at -1.81 USD per share versus 0.67 EUR a year earlier. Two analysts see quarterly revenue at 237.0 million USD versus 206.7 million EUR in the year-ago quarter. Five analysts forecast an average EPS of 9.94 USD for the current fiscal year and four analysts expect revenue averaging 1.12 billion USD (prior year 948.5 million EUR). » Más en finanzen.net

Datos financieros de la empresa

En el último trimestre, Viridian Therapeutics Aktie tuvo unos ingresos de 248,84 mil € y un beneficio neto de -111,38 M €

(EUR)	jun 2026	YoY
Ingresos	248,84 mil	291,07 %
Beneficio bruto	248,84 mil	291,07 %
Beneficio neto	-111,38 M	30,32 %
EBITDA	-104 M	22,45 %

Datos fundamentales

Métrica	Valor
Capitalización bursátil	2256,83 M €
Número de acciones	113,29 M
Máximo/mínimo de 52 semanas	29,60 € - 11,38 €
Dividendos	No
Beta	0,94
Ratio P/E	-6,54
Ratio PEG	-0,73
Ratio P/B	3,76
Ratio P/S	36,76

Perfil de la empresa

Viridian Therapeutics, Inc. ist ein Biotechnologieunternehmen, das Behandlungen für Patienten entwickelt, die an schweren Krankheiten leiden. Es entwickelt VRDN-001, einen humanisierten monoklonalen Anti-IGF-1R-Antikörper, der sich in der klinischen Phase 1/2 zur Behandlung der Schilddrüsenerkrankung (TED) befindet; VRDN-002, einen IGF-1R-Antikörper, der sich in der klinischen Phase 1 befindet; und VRDN-003, einen therapeutischen Antikörper gegen IGF-1R zur Behandlung von TED. Das Unternehmen war früher als Miragen Therapeutics, Inc. bekannt und änderte im Januar 2021 seinen Namen in Viridian Therapeutics, Inc. Viridian Therapeutics, Inc. wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Waltham, Massachusetts.

Nombre	Viridian Therapeutics Aktie
CEO	Stephen F. Mahoney
Sede	Waltham, ma Estados Unidos
Sitio web	viridiantherapeutics.com
Sector	Salud
Industria	Equipos y suministros sanitarios
Salida a bolsa	18/06/2014
Empleados	252